Therapeutic nanoparticles from novel multiblock engineered polyesterurethanes

Journal of Nanoparticle Research

Volumn 14, Issue 12, 2012, Pages

  Mattu, C ^a   Boffito, M ^a   Sartori, S ^a   Ranzato, E ^b   Bernardi, E ^c   Sassi, M P ^c   Di Rienzo, A M ^a   Ciardelli, G ^a,d  

^a POLITECNICO DI TORINO   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c ISTITUTO NAZIONALE DI RICERCA METROLOGICA   (Italy)

^d CNR   (Italy)

Author keywords

Cancer treatment; Controlled release; Nanoparticles; Polyesterurethanes; Solvent displacement

Indexed keywords

DEGRADATION; NANOPARTICLES; ONCOLOGY; POLYESTERS; POLYURETHANES; TARGETED DRUG DELIVERY;

BIODEGRA-DABLE MATERIALS; BIODEGRADABLE POLYURETHANES; CONTROLLED RELEASE; ENCAPSULATION EFFICIENCY; POLY(ECAPROLACTONE) (PCL); POLYESTERURETHANES; PREPARATION OF NANOPARTICLES; SOLVENT DISPLACEMENTS;

CONTROLLED DRUG DELIVERY;

COPOLYMER; NANOPARTICLE; PACLITAXEL; POLYCAPROLACTONE; POLYESTER; POLYESTERURETHANE; POLYETHER; POLYLACTIDE; UNCLASSIFIED DRUG; URETHAN DERIVATIVE;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEGRADATION; ENCAPSULATION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

EID: 84869888405     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-012-1306-6     Document Type: Article

References (48)

1. Anhorn MG, Mahler H, Langer K (2008) Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int J Pharm 363(1-2):162-169. doi:10.1016/j. ijpharm.2008.07.004.
2. Bogdanov B, Toncheva V, Schacht E, Finelli L, Sarti B, Scandola M (1999) Physical properties of poly(ester-urethanes) prepared from different molar mass polycaprolactonediols. Polymer 40:3171-3182. doi:10.1016/S0032-3861 (98)00552-7. (Pubitemid 30122612)
3. Bosworth LA, Downes S (2010) Physicochemical characterisation of degrading polycaprolactone scaffolds. Polym Degrad Stab 95(12):2269-2276. doi:10.1016/j.polymdegra dstab.2010.09.007.
4. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 54:631-651. doi:10.1016/S0169-409X(02) 00044-3. (Pubitemid 35247520)
5. Castro CA, Hogan JB, Benson KA, Shehata CW et al (1995) Behavioral effects of vehicles: DMSO ethanol, Tween-20, Tween-80 and emulphor-620. Pharmacol Biochem Behav 50(4):521-526. doi:10.1016/0091-3057(94)00331-9.
6. Cerrai P, Guerra CD, Lelli L, Tricoli M, Guerra RSD, Cascone MG, Giusti P (1994) Poly(ester-etherester) block copolymers as biomaterials. J Mater Sci Mater Med 5:33-39.
7. Chawla JS, Amiji M (2002) Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 249:127-138. doi:10.1016/S0378- 5173(02)00483-0. (Pubitemid 35333439)
8. Chen DR, Bei JZ, Wang SG (2000) Polycaprolactone microparticles and their biodegradation. Polym Degrad Stab 67:455-459. doi:10.1016/S0141-3910(99)00145- 7. (Pubitemid 32212633)
9. Cheng Q, Feng J, Chen J, Zhu X, Li F (2008) Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm Drug Dispos 29:431-439. doi:10.1002/bdd.621.
10. Ciardelli G, Rechichi A, Sartori S, D'Acunto M, Caporale A, Peggion E, Vozzi G, Giusti P (2006) Bioactive polyurethanes in clinical applications. Polym Adv Technol 17:786-789. doi:10.1002/pat.781. (Pubitemid 44883662)
11. Deshpande D, Devalapally H, Amiji M (2008) Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res 25(8):1936-1947. doi:10.1007/s11095-008-9614-3.
12. Dhanikula AB, Panchagnula R (1999) Localized paclitaxel delivery. Int J Pharm 183:85-100. doi:10.1016/S0378-51 73(99)00087-3. (Pubitemid 29257954)
13. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Delivery Rev 63:136-151. doi:10.1016/j.addr. 2010.04.009.
14. Fessi H, Puisieux F, Devissaguet J, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1-R4. doi:10.1016/0378-5173(89)90281-0. (Pubitemid 19247505)
15. Ge H, Hu Y, Yang S, Jiang X, Yang C (2000) Preparation, characterization, and drug release behaviors of drug-loaded e-caprolactone/L-lactide copolymer nanoparticles. J Appl Polym Sci 75(7):874-882. doi:10.1002/(SICI)1097-4628 (20000214)75:7\874:AID-APP3[3.0.CO;2-G. (Pubitemid 30527128)
16. Heijkants R, Van Calck RV, Van Tienen TG, De Groot JH, Buma P, Pennings AJ, Veth RPH, Schouten AJ (2005) Uncatalyzed synthesis, thermal and mechanical properties of polyurethanes based on poly(e-caprolactone) and 1, 4- butane diisocyanate with uniform hard segment. Biomaterials 26:4219-4228. doi:10.1016/j.biomaterials.2004.11. 005. (Pubitemid 40430848)
17. Kim D, Martin DC (2006) Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 27:3031-3037. doi:10.1016/j.biomaterials.2005.12.021. (Pubitemid 43208929)
18. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 75:1-18. doi:10.1016/j.colsurfb. 2009.09.001.
19. Kweon HE, Yoo MK, Park IK, Kim TH, Lee HC, Lee H, Oh J, Akaike T, Cho C (2003) A novel degradable polycaprolactone networks for tissue engineering. Biomaterials 24:801-808. doi:10.1016/S0142-9612(02)00370-8. (Pubitemid 35449832)
20. Lambda NMK, Woodhouse KA, Copper SL, Lelah MD (1998) Polyurethanes in biomedical applications. CRC press, Bocs Raton.
21. Leo E, Brina B, Forni F, Vandelli MA (2004) In vitro evaluation of PLA nanoparticles containing a lipophilic drug in watersoluble or insoluble form. Int J Pharm 278:133-141. doi: 10.1016/j.ijpharm.2004.03.002. (Pubitemid 38670444)
22. Lince F, Marchisio DL, Barresi AA (2008) Strategies to control the particle size distribution of poly-e-caprolactone nanoparticles for pharmaceutical applications. J Colloid Interface Sci 322:505-515. doi:10.1016/j.jcis.2008.03.033.
23. Lince F, Bolognesi S, Stella B, Marchisio DL, Dosio F (2011) Preparation of polymer nanoparticles loaded with doxorubicin for controlled drug delivery. Chem Eng Res Des 89(11):2410-2419. doi:10.1016/j.cherd.2011.03.010.
24. Martina M, Hutmacher DW (2007) Biodegradable polymers applied in tissue engineering research: a review. Polym Int 56:145-157. doi:10.1002/pi.2108. (Pubitemid 46165222)
25. Martinotti S, Ranzato E, Burlando B (2011) In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25(8):1568- 1574.
26. McDonald RT, McCarthy SP, Gross RA (1996) Enzymatic degradability of poly(lactide): effects of chain stereochemistry and material crystallinity. Macromolecules 29:7356- 7361. doi:10.1021/ma960513j. (Pubitemid 126525583)
27. McGuire WP, Markman M (2003) Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89:S3-S8. (Pubitemid 38067997)
28. Mora-Huertas CE, Fessi H, Elaissari A (2011) Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification- diffusion methods critical comparison. Adv Colloid Interface Sci 163:90-122.
29. Mu L, Feng SS (2003) A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86(1):33-48. doi:10.1016/S0168-3659(02)00320-6. (Pubitemid 35469120)
30. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G (2006) PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 325:172-179. doi:10.1016/j.ijpharm.2006.06.023. (Pubitemid 44573694)
31. Panchagnula R (1998) Pharmaceutical aspects of paclitaxel. Int J Pharm 172(1-2):1-15. doi:10.1016/S0378-5173(98) 00188-4. (Pubitemid 28430240)
32. Penco M, Sartore L, Bignotti F, D'Antone S, Di Landro L (2000) Thermal properties of a new class of block copolymers based on segments of poly(D, L-lactic-glycolic acid) and poly(e-caprolactone). Eur Polymer J 36:901-908. doi: 10.1016/S0014-3057(99)00155-X.
33. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. Methods for preparation of drugloaded polymeric nanoparticles. Nanomedicine 2:8-21. doi:10.1016/j.nano.2005.12.003.
34. Rechichi A, Ciardelli G, D'Acunto M, Vozzi G, Giusti P (2008) Degradable block polyurethanes from nontoxic building blocks as scaffold materials to support cell growth and proliferation. J Biomed Mater Res A 84:847-855. doi: 10.1002/jbm.a.31349. (Pubitemid 351294995)
35. Ribeiro HS, Chu BS, Ichikawa S, Nakajima M (2008) Preparation of nanodispersions containing b-carotene by solvent displacement method. Food Hydrocoll 22:12-17. doi: 10.1016/j.foodhyd.2007.04.009. (Pubitemid 47002056)
36. Singh J, Pandit S, Bramwell VW, Alpar HO (2006) Diphtheria toxoid loaded poly(e-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38(2):96-105. doi:10.1016/j.ymeth.2005.11.003. (Pubitemid 43163469)
37. Stearns ME, Wang M (1992) Taxol blocks processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res 52:3776-3781.
38. Tsuji H, Miyauchi S (2001) Poly(L-lactide): effects of crystallinity on enzymatic hydrolysis of poly(L-lactide) without free amorphous region. Polym Degrad Stab 71(3):415- 424. doi:10.1016/S0141-3910(00)00191-9. (Pubitemid 32196226)
39. Vermette P, Griesser HJ, Laroche G, Guidoin R (2001) Biomedical application of polyurethanes. Landes Bioscience, Georgetown.
40. Vozzi G, Rechichi A, Dini F, Salvadori C, Vozzi F, Burchielli S, Carlucci F, Arispici M, Ciardelli G, Giusti P, Ahluwalia A (2008) PAM-microfabricated polyurethane scaffolds: in vivo and in vitro preliminary studies. Macromol Biosci 8:60-68. doi:10.1002//mabi.2007002114.
41. Weiszhár Z, Czúcz J, Révész C, Rosivall J, Rozsnyay Z (2012) Complement activation by polyethoxylated pharmaceutical surfactants Cremophor-EL Tween-80 and Tween-20. Eur J Pharm Sci 45(4):492-498. doi:10.1016/j.ejps.2011. 09.016.
42. Wenk MR, Fahr A, Reszka R, Seelig J (1996) Paclitaxel partitioning into lipid bilayers. J Pharm Sci 85(2):228-231. doi: 10.1021/js950120i. (Pubitemid 26055806)
43. Yen WC, Wientjes MG, Au JL (1996) Differential effect of taxol in rat primary and metastatic prostate tumors: site dependent pharmacodynamics. Pharm Res 13(9):1305-1312. doi: 10.1023/A:1016053412582. (Pubitemid 26344972)
44. Zanetti-Ramos BG, Lemos-Senna E, Soldi V, Borsali R, Cloutet E, Cramail H (2006) Polyurethane nanoparticles from a natural polyol via miniemulsion technique. Polymer 47:8080-8087. doi:10.1016/j.polymer.2006.09.057. (Pubitemid 44647370)
45. Zanetti-Ramos BG, Lemos-Senna E, Cramail H, Cloutet E, Borsali R, Soldi V (2008) The role of surfactant in the miniemulsion polymerization of biodegradable polyurethane nanoparticles. Mater Sci Eng C 28(2008):526-531. doi:10.1016/j.msec.2007.04.041. (Pubitemid 351417802)
46. Zavisova V, Koneracka M, Strbak O, Tomasovicova N, Kopcansky P, Timko M, Vavra I (2007) Encapsulation of indomethacin in magnetic biodegradable polymer nanoparticles. J Magn Magn Mater 311:379-382. doi:10.1016/j.jmmm.2006.11.177. (Pubitemid 46401000)
47. Zhang Z, Feng SS (2006) Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27:262-270. doi:10.1016/j.biomaterials.2005. 05.104. (Pubitemid 41278528)
48. Zili Z, Sfar S, Fessi H (2005) Preparation and characterization of poly-epsilon-caprolactone nanoparticles containing griseofulvin. Int J Pharm 294:261-267. doi:10.1016/j.ijpharm. 2005.01.020. (Pubitemid 40462340)